1)Yamaki K, Takiyama K, Itho N et al:Experimentally induced Vogt-Koyanagi-Harada disease in two Akita dogs. Exp Eye Res 80:273-280, 2005
2)Takase H, Yu CR, Ham DI et al:Inflammatory processes triggered by TCR engagement or by local cytokine expression:differences in profiles of gene expression and infiltrating cell populations. J Leukoc Biol 80:538-545, 2006
3)Brito BE, O'Rourke LM, Pan Y et al:IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci 40:2583-2589, 1999
4)Verma MJ, Lloyd A, Rager H et al:Chemokines in acute anterior uveitis. Curr Eye Res 16:1202-1208, 1997
5)Okada AA, Goto H, Ohno S et al:Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 130:592-598, 2012
6)Fine HF, Baffi J, Reed GF et al:Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132:794-796, 2001
7)Cordero Coma M, Sobrin L, Onal S et al:Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114:1574-1579, 2007
8)Verbsky JW:Therapeutic use of T regulatory cells. Curr Opin Rheumatol 19:252-258, 2007
9)Nussenblatt RB, Gery I, Weiner HL et al:Treatment of uveitis by oral administration of retinal antigens:results of a phase Ⅰ/Ⅱ randomized masked trial. Am J Ophthalmol 123:583-592, 1997
10)Biester S, Deuter C, Michels H et al:Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91:319-324, 2007
11)Mushtaq B, Saeed T, Situnayake RD et al:Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 21:824-825, 2007
12)Reddy AR, Backhouse OC:Does etanercept induce uveitis? Br J Ophthalmol 87:925, 2003
13)Nussenblatt RB, Fortin E, Schiffman R et al:Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb:a phase Ⅰ/Ⅱ clinical trial. Proc Natl Acad Sci USA 96:7462-7466, 1999
14)Nussenblatt RB, Thompson DJ, Li Z et al:Humanized anti-interleukin-2(IL-2)receptor alpha therapy:long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21:283-293, 2003